Design Therapeutics (DSGN) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.32

Estimate

-$0.35

Surprise

+7.6%

Score today

5.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Design Therapeutics (DSGN) reported a narrower loss than forecast — adjusted EPS of -$0.32 against the -$0.35 estimate (a 7.6% beat on a still-unprofitable quarter).

• RBC Capital Markets Adjusts Price Target for Design Therapeutics — fiscal.ai, 2026-11-05
• RBC Capital Maintains Outperform on Design Therapeutics, Lowers Price Target to $19 — benzinga, 2026-11-05
• Design Therapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-05

TrendMatrix currently rates DSGN Sell at 5.5/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +7.6% surprise compares with a +12.9% four-quarter average. Next scheduled report: 2027-03-09.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$10.23

Price target

$18.89

Stop

$9.52

Upside to target

+84.6%

Reward-to-risk

6.9:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$605.2M

P/E (fwd)

-6.0

52-week range

$6.23–$17.25

Off 52-week high

40.7%

RSI (14)

46

Volume vs avg

0.24×

Score today

5.5/10